Charles Richardson M.D.
Academic Title: Clinical Assistant Professor
Primary Appointment: Psychiatry
crichard@mprc.umaryland.edu
Location: IPHB P1G08
Phone: (410) 402-6871

Personal History

1974:  B.A. (Chemistry and Math) University of North Carolina – Chapel Hill
1981:  M.A. (Cultural Anthropology)  University of North Carolina – Chapel Hill
1985:  M.D.  School of Medicine, University of North Carolina – Chapel Hill
1985-1989:  Residency Training in Psychiatry: Western Psychiatric Institute and Clinic, University of Pittsburgh
1990:  Certification,  American Board of Psychiatry and Neurology
1989 – present:  Staff Psychiatrist, Spring Grove Hospital Center
1993 – present:  Clinical Unit Director,  Treatment Research Unit, Spring Gove Hospital Center

Clinical Speciality

Dr. Richardson is the lead clinician for the Treatment Research Program.  He supervises the overall clinical program and directs the execution of research protocols, while contributing to protocol development and analysis.

Publications

Hernandez DE, Richardson CM, Nemeroff CB, Orlando RC, St-Pierre S, Rioux F, and Prange AJ: "Evidence of biological activity of two N-terminal fragments of neurotensin:  neurotensin 1-8 and neurotensin 1-10," Brain Research, 301:153-156,1984.

Bissette G, Richardson CM, Kizer JS, and Nemeroff CB:  "Ontogeny of brain neurotensin in the rat: A radioimmuno-assay study,"  Journal of Neurochemistry, 43:283-287, 1984.

Goldstein MZ and Richardson CM:  "Meningioma with Depression:  ECT Risk or Benefit?,"Psychosomatics, 29:349-351, 1988.

Conley R, Richardson C, Kent D, Gounaris C, Zaremba S:  Clozapine Response Varies in Deficit vs Non-Deficit Schizophrenic Subjects.  Biological Psychiatry, 35(9): 746, 1994.

Richardson C, Conley R:  Clozapine Response in Schizophrenic Subjects with Neuroleptic Resistant Disorganization.  Schizophrenia Research, 15(1):162, 1995.

Richardson C, Conley R:  Olanzapine response in schizophrenic subjects with neuroleptic resistant disorganization.  Schizophrenia Research, 24 (1,2):191, March 1997.

Conley R, Tamminga C, Bartko J, Richardson C, Peszke M, Lingle J, Hegerty J, Love R, Gounaris C, and Zaremba S: Olanzapine Compared With Chlorpromazine in Treatment-Resistant Schizophrenia.  American Journal of Psychiatry, 155(7):914-920, 1998.

Conley R, Tamminga C, Kelly D, Richardson C: Treatment-Resistant Schizophrenic Patients Respond to Clozapine after Olanzapine Non-Response.  Biological Psychiatry, 46:73-77, 1999.

Richardson C, Zaremba S, Kelly D, Conley R: Clozapine Treatment After Olanzapine Nonresponse:Effects on Hostility.  Schizophrenia Research, 36(1-3):294, 1999.

Richardson C, Kelly DL, Conley RR:  Biperiden for excessive sweating from clozapine.  American Journal  of Psychiatry, 158(8): 1329-30, 2001.

Conley RR, Kelly DL, Richardson CM, Tamminga CA, Carpenter WT Jr.  The efficacy of high dose olanzapine versus clozapine in treatment-resistant schizophrenia: a double-blind crossover study.  Journal of Clinical Psychopharmacology, 23(6):668-71, 2003.

Kelly DL, Conley RR, Richardson CM, Tamminga CA, Carpenter WT Jr.  Adverse effects and laboratory parameters of high-dose olanzapine vs. clozapine in treatment-resistant schizophrenia.  Annals of Clinical Psychiatry.  15(3-4):181-6, 2003.

Conley RR, Kelly DL, Beason-Held LL, Holcomb HH, Richardson CM.  The effects of clozapine and high-dose olanzapine on brain function in treatment-resistant schizophrenia: A case study.  Journal of Psychopharmacology, 18(3):429-31, 2004.




Faculty members: Click here to update your contact information and create a profile.


This site will work and look much better in a modern web browser, such as Internet Explorer 6, Firefox, or Safari 1.2 (Mac)
© University of Maryland School of Medicine